Pipeline Overview

The Genetix clinical pipeline includes: Lenti-D for Adrenoleukodystrophy (ALD) now in development, and LentiGlobin™ for Thalassemia/Sickle Cell Disease also in clinical development. 

In addition to these initial disease targets, the company’s technology is also applicable to the treatment of other genetic diseases.